Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating income | — | -$13.0M | -$108M | -$9.14M | -$25.5M |
| Net income | — | -$14.0M | -$98.3M | -$9.41M | -$25.0M |
| EPS (diluted) | — | -$0.99 | -$1,089.70 | -$8.48 | -$4.18 |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | — | -$1.49M | -$8.72M | -$7.52M | -$5.11M |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $329K | $5.90M | $3.14M | $1.53M | $102K |
| Total assets | $77.1M | $119M | $22.1M | $20.6M | $348K |
| Total liabilities | $3.65M | $18.5M | $11.0M | $12.1M | $12.7M |
| Shareholders' equity | -$2.26M | $99.7M | $11.1M | $8.52M | -$12.4M |
| Retained earnings | -$2.26M | -$4.92M | -$103M | -$113M | -$138M |
| Shares (wtd avg diluted) | — | 24.2M | 97.5B | 1.11M | 5.96M |
Every figure is extracted from ZyVersa Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.